EUVIMEDEUVIMED entdecken
Crossref

Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae

Junjie Lan, Weiping Wu, Liupin Du, Qi Liu

Archives of Virology · 2026

DOI: 10.1007/s00705-026-06544-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Virology, 2026. Verfasst von Junjie Lan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Second People's Hospital of Lishui, Lishui, 323000, Zhejiang, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Bacteriophages, Klebsiella Infections, Phage Therapy. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Science and Technology Planning Project of Lishui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) constitutes a substantial hazard to human health. Phage therapy represents a promising alternative for treating CRKP infections. This research isolated a novel phage, vB_LSKP32, which targets the KL64 capsular type of CRKP from hospital sewage samples. The phage vB_LSKP32 adsorbs rapidly to host cells, features a 5–10 min latent period, and yields approximately 56 ± 3 new phage particles per infected cell. It remains stable and infectious under conditions ranging from 4 °C to 50 °C and pH 4 to 11. The phage vB_LSKP32 genome contains a 40,942 bp linear dsDNA with a GC content of 52.92%. Genome annotation predicted 50 ORFs, with no evidence of antibiotic resistance genes, virulence genes, lysogeny-related genes and tRNA. Through intergenomic similarity studies and phylogenetic analyses, vB_LSKP32 was classified as a novel species within the genus Przondovirus, family Autographiviridae. Phage vB_LSKP32 exhibited efficient suppression of host bacterial proliferation for approximately 7 h in vitro. Moreover, it significantly enhanced the survival rate of Galleria mellonella larvae post-infection, with the survival rate positively correlating with phage titer. Notably, larvae treated at an MOI of 100 elevated the survival rate to 90% (vs. 15% in controls). Our findings suggest that phage vB_LSKP32 shows significant potential as an antimicrobial agent against KL64-type CRKP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeBacteriophagesKlebsiella InfectionsPhage TherapyCarbapenem-Resistant EnterobacteriaceaePhylogenyAnimalsCarbapenemsGenome, ViralHumansAnti-Bacterial AgentsSewageBase Composition

Substanzen

CarbapenemsAnti-Bacterial AgentsSewage

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The Second People's Hospital of Lishui, Lishui, 323000, Zhejiang, China.
  • Department of Clinical Laboratory, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
  • Department of Clinical Laboratory, Lishui People's Hospital, Lishui, 323000, Zhejiang, China. liuqi1359@163.com.

Förderung

  • Science and Technology Planning Project of Lishui

Zitieren

APA

Lan, J., Wu, W., Du, L., & Liu, Q. (2026). Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae. Archives of Virology. https://doi.org/10.1007/s00705-026-06544-1

Vancouver

Lan J, Wu W, Du L, Liu Q. Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae. Archives of Virology. 2026. doi:10.1007/s00705-026-06544-1

BibTeX
@article{Lan2026,
  author = {Lan, Junjie and Wu, Weiping and Du, Liupin and Liu, Qi},
  title = {Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae},
  journal = {Archives of Virology},
  year = {2026},
  doi = {10.1007/s00705-026-06544-1}
}
Kostenlos starten →